Based on the important role of stroma in supporting tumor growth and the activity of TEM-1 on supporting tumor stromal cell functions, clinical studies using a humanized monoclonal antibody called ontuxizumab (MORAb-004) are currently being conducted to determine the safety and clinical activity of blocking TEM-1 function in patients with various cancer types [28]. Here, CD248 is linked to cancer.